Treating life-threatening intracranial aneurysms with flow modulating devices (FMDs) is mostly successfull, but may lead to complications and even delayed aneurysm rupture. A biomarker indicating treatment success is direly needed. Flow MRI can detect flow reduction, but it is impaired by metal artifacts from FMDs. Black-blood (BB) MRI is less sensitive to metal artifacts and often results in poor slow-flow suppression. We hypothesize that BB contrast changes after aneurysm treatment. Here, after placing FMDs in 3D-printed aneurysm models, an enhanced signal was found on BB MRI, associated with the reduced aneurysmal flow after flow modulation and thus possible treatment success.
No takes yet. Share an insight, caveat, or question.
Pravdivtseva et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: